Brain, Vol. 125, No. 1, 22-31,
January 1, 2002
© 2002 Oxford University Press
Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy
1Epilepsy Research Group, University Department of Clinical Neurology and 2Department of Neuropathology, Institute of Neurology, 3Department of Neuropathology, Institute of Child Health, University College London, London and 4Department of Neuropathology, Radcliffe Infirmary, Oxford, UK Correspondence to: Dr S. M. Sisodiya, Epilepsy Research Group, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK E-mail: sisodiya{at}ion.ucl.ac.uk
Epilepsy is resistant to drug treatment in about one-third of cases, but the mechanisms underlying this drug resistance are not understood. In cancer, drug resistance has been studied extensively. Amongst the various resistance mechanisms, overexpression of drug resistance proteins, such as multi-drug resistance gene-1 P-glycoprotein (MDR1) and multidrug resistance-associated protein 1 (MRP1), has been shown to correlate with cellular resistance to anticancer drugs. Previous studies in human epilepsy have shown that MDR1 and MRP1 may also be overexpressed in brain tissue from patients with refractory epilepsy; expression has been shown in glia and neurones, which do not normally express these proteins. We examined expression of MDR1 and MRP1 in refractory epilepsy from three common causes, dysembryoplastic neuroepithelial tumours (DNTs; eight cases), focal cortical dysplasia (FCD; 14 cases) and hippocampal sclerosis (HS; eight cases). Expression was studied immunohistochemically in lesional tissue from therapeutic resections and compared with expression in histologically normal adjacent tissue. With the most sensitive antibodies, in all eight DNT cases, reactive astrocytes within tumour nodules expressed MDR1 and MRP1. In five of eight HS cases, reactive astrocytes within the gliotic hippocampus expressed MDR1 and MRP1. Of 14 cases of FCD, MDR1 and MRP1 expression was noted in reactive astrocytes in all cases. In five FCD cases, MRP1 expression was also noted in dysplastic neurones. In FCD and DNTs, accentuation of reactivity was noted around lesional vessels. Immunoreactivity was always more frequent and intense in lesional reactive astrocytes than in glial fibrillary acidic protein-positive reactive astrocytes in adjacent histologically normal tissue. MDR1 is able to transport some antiepileptic drugs (AEDs), and MRP1 may also do so. The overexpression of these drug resistance proteins in tissue from patients with refractory epilepsy suggests one possible mechanism for drug resistance in patients with these pathologies. We propose that overexpressed resistance proteins lower the interstitial concentration of AEDs in the vicinity of the epileptogenic pathology and thereby render the epilepsy caused by these pathologies resistant to treatment with AEDs.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. J. Vecht and M. van Breemen Optimizing therapy of seizures in patients with brain tumors Neurology, December 26, 2006; 67(12_suppl_4): S10 - S13. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Jandova, D. Pasler, L. L. Antonio, C. Raue, S. Ji, M. Njunting, O. Kann, R. Kovacs, H.-J. Meencke, E. A. Cavalheiro, et al. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices Brain, December 1, 2006; 129(12): 3290 - 3306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dallas, D. S. Miller, and R. Bendayan Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev., June 1, 2006; 58(2): 140 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Remy and H. Beck Molecular and cellular mechanisms of pharmacoresistance in epilepsy Brain, January 1, 2006; 129(1): 18 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bronger, J. Konig, K. Kopplow, H.-H. Steiner, R. Ahmadi, C. Herold-Mende, D. Keppler, and A. T. Nies ABCC Drug Efflux Pumps and Organic Anion Uptake Transporters in Human Gliomas and the Blood-Tumor Barrier Cancer Res., December 15, 2005; 65(24): 11419 - 11428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Clinckers, I. Smolders, A. Meurs, G. Ebinger, and Y. Michotte Quantitative in Vivo Microdialysis Study on the Influence of Multidrug Transporters on the Blood-Brain Barrier Passage of Oxcarbazepine: Concomitant Use of Hippocampal Monoamines as Pharmacodynamic Markers for the Anticonvulsant Activity J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 725 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Volk and W. Loscher Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures Brain, June 1, 2005; 128(6): 1358 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Volk, H. Potschka, and W. Loscher Immunohistochemical Localization of P-glycoprotein in Rat Brain and Detection of Its Increased Expression by Seizures Are Sensitive to Fixation and Staining Variables J. Histochem. Cytochem., April 1, 2005; 53(4): 517 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Boison Adenosine and Epilepsy: From Therapeutic Rationale to New Therapeutic Strategies Neuroscientist, February 1, 2005; 11(1): 25 - 36. [Abstract] [PDF]
|
|
|
|
|
|
F. Zimprich, R. Sunder-Plassmann, E. Stogmann, A. Gleiss, A. Dal-Bianco, A. Zimprich, S. Plumer, C. Baumgartner, and C. Mannhalter Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy Neurology, September 28, 2004; 63(6): 1087 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weiss, C. J. Kerpen, H. Lindenmaier, S.-M. G. Dormann, and W. E. Haefeli Interaction of Antiepileptic Drugs with Human P-Glycoprotein in Vitro J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 262 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Siddiqui, R. Kerb, M. E. Weale, U. Brinkmann, A. Smith, D. B. Goldstein, N. W. Wood, and S. M. Sisodiya Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter Gene ABCB1 N. Engl. J. Med., April 10, 2003; 348(15): 1442 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Pedley and M. Hirano Is Refractory Epilepsy Due to Genetically Determined Resistance to Antiepileptic Drugs? N. Engl. J. Med., April 10, 2003; 348(15): 1480 - 1482. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Brodie and J. P. Leach Success or failure with antiepileptic drug therapy: Beyond empiricism? Neurology, January 28, 2003; 60(2): 162 - 163. [Full Text] [PDF]
|
|
|
|
|
|
D. S. Cox, K. R. Scott, H. Gao, and N. D. Eddington Effect of P-Glycoprotein on the Pharmacokinetics and Tissue Distribution of Enaminone Anticonvulsants: Analysis by Population and Physiological Approaches J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1096 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Loscher and H. Potschka Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 7 - 14. [Abstract] [Full Text] [PDF]
|
|